Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Galapagos on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri May 08, 12:15PM CDT
JNJ: 99.53 (+1.13), ABBV: 69.23 (+1.26)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 99.53 (+1.13)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 232.32 (+8.93), ACT: 298.98 (-2.94), MDT: 74.37 (+1.28), XON: 46.54 (+1.02), CTIC: 1.91 (+0.03), PFNX: 19.47 (+0.49), JNJ: 99.53 (+1.13), ANTM: 159.73 (+1.15), NVAX: 11.98 (-0.13), SHPG: 250.34 (+7.35), ABBV: 69.23 (+1.26), TBPH: 12.29 (+0.36), SNY: 51.49 (+2.71), ALQA: 5.19 (+0.09), REGN: 526.01 (+16.98), ONCY: 0.58 (+0.03), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), EPRS: 6.00 (+0.35), AMGN: 154.10 (+2.79), NKTR: 11.40 (+0.22), ZTS: 46.96 (+0.39), GILD: 113.74 (+0.38), ACHN: 8.68 (+0.14), GERN: 4.22 (+0.13)
Galapagos awarded €1.6M grant to develop Hep B therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:44AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 69.23 (+1.26)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 5.06 (+0.04), AGEN: 9.17 (+0.31), NVAX: 11.98 (-0.13), ALXN: 192.53 (+4.37), PPHM: 1.29 (+0.06), THLD: 4.18 (+0.12), GSK: 42.45 (+0.65), OMER: 17.33 (+0.29)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 69.23 (+1.26)